An observational study in Kawasaki Disease, Chest X-ray for Clinical Evaluation and Mucocutaneous Lymph Node Syndrome, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 0 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · China.
Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 14th registered.
62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.
Browse Mucocutaneous Lymph Node Syndrome studies →8 of the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Children's Hospital of Fudan University · Sites in China
Ages 2–18
Children's Hospital of Fudan University · Sites in China
Ages 1 mo–18 yrs
Children's Hospital of Fudan University · Sites in China
Ages 2–18
West China Second University Hospital · Sites in China
Ages up to 18 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 6 · Phase 4 2
First in 2013; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 284 across 24 observational studies indexed under Mucocutaneous Lymph Node Syndrome.
Median enrollment 65 across the 8 interventional studies, 650 across the 8 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 5 most frequent:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 225 studies on the registry; 55 are open to participants now.
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine has 1 study filed under Mucocutaneous Lymph Node Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Mucocutaneous Lymph Node Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530640Phase 3Children's Hospital of Fudan UniversityStatins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities | 2027-08-31 |
| NCT07686770Phase 3Children's Hospital of Fudan UniversityEfficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease | 2027-09-01 |
| NCT07405658Xinhua Hospital, Shanghai Jiao Tong University School of MedicineClinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease | 2026-12-31 |
| NCT05643651Children's Hospital of Fudan UniversityRivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to develop an AI-based early warning system for Kawasaki Disease (KD) using chest X-rays (CXR) in children diagnosed with Kawasaki Disease. The main question[s] it aims to answer are:
Participants will:
Provide retrospective data on chest X-rays and clinical data (CRP, coronary ultrasound, etc.) Allow analysis of CXR features using deep learning models to extract relevant patterns Have their data incorporated into a federated learning model to ensure privacy and data security
Research Objectives and Technical Approach Core breakthrough: First time using routine chest X-rays (CXR) to develop an AI-based early warning model.
Technical path: Multi-center data integration, collection of CXR and clinical data (clinical symptoms, laboratory tests, coronary ultrasound, etc.), and a federated learning framework to ensure privacy and security. Exploration of imaging biomarkers and CXR features that are invisible to the human eye, as well as the development of a multi-modal dynamic early warning model.
Dual-path CNN to extract CXR features → Graph neural networks to integrate laboratory indicators → Diagnosis model to output the risk score of kawasaki disease.↑
Innovation Advantages and Clinical Value Early-warning performance was strong by day 3 of fever, achieving a pre-trial sensitivity of 87.2% for Kawasaki disease, while providing individualized IVIG treatment windows and predicted coronary-artery risk. The lightweight model (less than 50MB) is adaptable for use in primary care settings.
Clinical pathway:
AI identifies high-risk children → Priority for echocardiography → IVIG treatment window advanced → Reduction in cardiovascular complications.
The ultimate goal is to shorten diagnosis time and reduce cardiovascular complications of KD patients in China.
Validation Plan and Results Translation
Three-phase validation:
Internal: 5-fold cross-validation (AUC ≥0.88) External: Blind testing in 3 hospitals (sensitivity >85%, specificity >80%) Clinical: Real-time deployment in emergency settings (response time ≤15 seconds) Results translation: 1-2 peer-reviewed journal publications and 1-2 patent filings; facilitating early identification of Kawasaki disease, thereby improving clinical outcomes.
The case group consists of children diagnosed with Kawasaki Disease (KD) over the past 10 years. The inclusion criteria include: Children diagnosed with Kawasaki Disease based on clinical symptoms and confirmed by medical records.
The control group consists of data from patients with fever lasting ≥3 days, matched to the KD cohort based on diagnosis year, month, and clinical characteristics.
The study focuses on examining the relationship between chest X-ray features and Kawasaki Disease in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Case group
Control group
Exclusion Criteria:
Case group
Control group
Inclusion criteria: (1) The age of seeking medical treatment is less than or equal to 18 years old; (2) The medical record system diagnosis contains the diagnosis of "Kawasaki Disease", "mucocutaneous lymph node syndrome" or "IVIG non-response Kawasaki disease". (3) At least one complete chest X-ray examination data (images and reports) is available during the same hospitalization. Exclusion criteria: (1) Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures. (2) Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever. (3) Inability to determine the final diagnosis (such as loss to follow-up, diagnosis in doubt).
Diagnostic Test: AI-Based Early Warning System for Kawasaki Disease
Inclusion criteria: (1) The age of seeking medical treatment is less than or equal to 18 years old; (2) The same period as the case group; (3) Fever lasts for 3 days or more; (4) Rule out the possibility of diagnosing Kawasaki disease Exclusion criteria: (1) Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures. (2) Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever. (3) Inability to make a clear final diagnosis (such as loss to follow-up, questionable diagnosis)
Diagnostic Test: AI-Based Early Warning System for Kawasaki Disease
This study utilizes an AI-based early warning system for Kawasaki Disease (KD) to predict the optimal IVIG treatment window and assess coronary risk. The system analyzes chest X-ray (CXR) images and integrates them with clinical data such as CRP levels and clinical symptoms. The intervention involves the development of a multi-modal dynamic prediction model that uses a dual-pathway convolutional neural network (CNN) to extract relevant CXR features and a graph neural network to integrate laboratory indicators. The AI system outputs a prediction of the IVIG treatment window and estimates the risk of coronary artery damage. This early warning system aims to reduce diagnosis time and improve treatment outcomes by identifying high-risk KD patients earlier, enabling timely intervention and personalized treatment plans. The model is designed to be lightweight (under 50MB) to be easily applicable in primary care settings.
Area Under Curve
Time frame: Up to 14 days after fever onset
sensitivity
Time frame: Up to 14 days after fever onset
specificity
Time frame: Up to 14 days after fever onset
Plan to share: No — Due to confidentiality concerns, participant consent restrictions, and the need to comply with ethical and legal standards, Individual Participant Data (IPD) from this study will not be shared. The data contains sensitive health information that is protected by privacy regulations, and we do not have explicit consent from participants to share their data for secondary analysis. Additionally, institutional policies and data security requirements further restrict the release of IPD.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mucocutaneous Lymph Node Syndrome →
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine →